GDNA

$68.46prev close

Compare

No price history available for this symbol yet.

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Asset Management

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
GDNAGoldman Sachs Human Evolution ETF	$68.46	+0.28%	$60M	—
ABLDAbacus FCF Real Assets Leaders ETF	$32.20	+0.35%	$83M	—
ADMEAptus Drawdown Managed Equity ETF	$55.76	-0.30%	$293M	—
APRWAllianzIM U.S. Equity Buffer20 Apr ETF	$37.68	-0.12%	$201M	—
BMVPInvesco Bloomberg MVP Multi-factor ETF	$53.84	-0.19%	$101M	—
EXIVVelocityShares 1x Daily Inverse VSTOXX Futures ETN	$7.45	+0.40%	$60M	—
GDATGoldman Sachs Data-Driven World ETF	$72.70	+0.21%	$52M	—

Source: Financial Modeling Prep · peers by sector/industry

Fund

The investment seeks to provide investment results that closely correspond, before fees and expenses, to the performance of the Goldman Sachs Human Evolution Index (the "index"). The fund seeks to achieve its investment objective by investing at least 80% of its assets in securities included in its underlying index. The index is designed to deliver exposure to companies with common equity securities listed on exchanges in certain developed markets that may benefit from the development of new knowledge, medicines and technologies for the medical treatment of the human condition, from birth to end-of-life care.

Expense ratio: 0.50%
Assets: $60M
Holdings: 0
Inception: 2019-03-01
Issuer: Goldman

No constituent disclosure available for this fund yet.

Goldman Sachs Human Evolution ETF

This fund's primary objective is to achieve investment returns that closely track the performance of the Goldman Sachs Human Evolution Index, prior to accounting for fees and expenses. To accomplish this, the fund allocates at least 80% of its total assets to the equities that comprise its underlying index. The index itself is constructed to provide exposure to common stocks of companies in specific developed markets. These companies are identified for their potential to capitalize on breakthroughs in scientific knowledge, pharmaceutical development, and technological innovations related to human medical care, addressing conditions throughout an individual's entire life journey, from birth to end-of-life.

IPO / List date: Mar 1, 2019

Held by traders on TradeandTell

No one on the platform currently holds GDNA.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in GDNA as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded GDNA yet.